Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Apolipoprotein C-IV–apolipoprotein C-II readthrough (NMD candidate) (APOC4-APOC2)
- Target
- APOC4-APOC2
- Molecular classification
- Other (Non-coding RNA, readthrough transcript, NMD candidate)
01
Overview
The "Apolipoprotein C-IV–apolipoprotein C-II readthrough (NMD candidate)" transcript results from read-through transcription between the adjacent APOC4 and APOC2 genes on chromosome 19. It is classified as a candidate for nonsense-mediated mRNA decay, and therefore, it is unlikely to be translated into a functional protein. There is no evidence supporting a physiological or pharmacological role for this readthrough transcript, and it is not considered a receptor, enzyme, transporter, or other canonical drug target[1][3]. Disease phenotypes and functional roles attributed to this genomic region are due to the parental APOC2 and APOC4 genes, not to the readthrough product itself.
- Other names
- APOC4-APOC2 readthroughAPOC4-APOC2APOC4
02
Biological functions
Other (No known direct biological function, as it is unlikely to produce a protein; may only represent transcriptional noise or regulatory non-coding RNA)
03
Disease associations
Other (Linked by proximity/association to Apolipoprotein C-II and C-IV, which are involved in lipid metabolism and are associated with diseases such as hypertriglyceridemia and apolipoprotein C-II deficiency, but the readthrough transcript itself is not known to play any direct disease role)
Beyond the preview
Go deeper on Apolipoprotein C-IV–apolipoprotein C-II readthrough (NMD candidate) (APOC4-APOC2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Apolipoprotein C-IV–apolipoprotein C-II readthrough (NMD candidate) (APOC4-APOC2).